The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden-Reference-Cited by-同舟云学术

The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden

Published:2021-01-01 Issue:1 Volume:24 Page:447-457
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Nilsson Fredrik O. L.¹,Gal Peter²,Houisse Ivan²,Ivanova Jasmina I.³,Asanin Sandra T.⁴

Affiliation:

1. Health and Value Sweden, Pfizer Innovations AB, Stockholm, Sweden

2. Evidence Synthesis, Modeling & Communication, Evidera, Budapest, Hungary

3. Global Health Economics and Outcomes Research (Oncology), Pfizer Inc, New York, NY, USA

4. Oncology Sweden, Pfizer Innovations AB, Stockholm, Sweden

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1901722

Reference85 articles.

1. EGFR mutation testing in non-small cell lung cancer (NSCLC)

2. Molecular analysis of EGFR gene in different types of tumor material from NSCLC patients

3. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

4. Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

5. Overview of current systemic management of EGFR-mutant NSCLC

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

2. A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC);Expert Opinion on Pharmacotherapy;2022-07-04

3. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis;Frontiers in Public Health;2022-04-15